Who we are
ABOUT MEDICINES FOR EUROPE
PURPOSE AND OBJECTIVES
OUR VALUES – OUR 5 PILLARS
STRUCTURE
MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
Vacancies
Manifesto 2024
Key topics
ACCESS
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
ENVIRONMENT
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
COVID-19
Publications
EXTERNAL RESOURCES
FACTSHEETS
INFOGRAPHICS
PODCAST
POLICY
REPORTS
VIDEOS
Newsroom
IN THE NEWS
PRESS RELEASES
Contact us
Login
Generic medicines
Home
Medicines for Europe
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Medicines for Europe
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
Publications
Filters:
Value added medicines
x
By group
By type
External Resources
Factsheets
Infographics
PODCAST
Policy
Reports
Videos
Newsroom
Twitter
Tweets
Videos
Photos
Position Paper. Incentives Review The Orphan and Paediatric Incentives
1 March 2021
Policy
Read More
Digital VAM – Benefit to Patients
28 February 2021
Infographic
Read More
Digital VAM – challenges
28 February 2021
Infographic
Read More
Adherence to therapy infographic
28 February 2021
Infographic
Read More
Electronic product information: from principles to actions. AESGP, EFPIA and Medicines for Europe reflections on EMAHMA – EC Key principles for electronic product information
10 February 2021
Report
Read More
Filling the gap: How off-patent medicines can improve the equity and quality of cancer care
4 February 2021
Report
Read More
Filling the gap: How off-patent medicines can improve the equity and quality of cancer care
4 February 2021
Factsheet
Read More
White Paper: Anatomy of a failure to launch: A review of barriers to generic and biosimilar market entry and the use of competition law as a remedy
5 November 2020
Report
Read more
Second wave pandemic preparedness: procurement principles
24 August 2020
Policy
Read More
Policy Roadmap for Medicines Manufacturing Leadership
6 July 2020
Policy
Read More
Posts navigation
1
2
3
4
5
6
…
9
Subscribe to our newsletter
[contact-form-7 id="1638" title="Newsletter subscription"]
Medicines For Europe
Who we are
Vacancies
Manifesto 2024
Key topics
Publications
Newsroom
Contact us
SECTOR GROUPS
Generic medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Biosimilar medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Value added medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
Events
Tweet
Tweet
Tweet
LinkedIn